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Abstract: BACKGROUND AND OBJECTIVES The University of California Los Angeles Scleroderma
Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 (UCLA GIT 2.0) is validated to capture
gastrointestinal (GI) tract morbidity in patients with systemic sclerosis (SSc). The aims of this study
were to determine in a large SSc cohort if the UCLA GIT 2.0 is able to discriminate patients for whom
a rheumatologist with experience in SSc would recommend an esophago-gastro-duodenoscopy (EGD),
and if it could identify patients with endoscopically proven esophagitis or with any pathologic finding
on EGD. METHODS We selected patients fulfilling the ACR/EULAR 2013 criteria for SSc from our
EUSTAR center having completed at least once the UCLA GIT 2.0 questionnaire, and we collected data
on gastrointestinal symptoms and EGD from their medical charts. We analyzed by general linear mixed
effect models several parameters, including UCLA GIT 2.0, considered as potentially associated with the
indication of EGD, as well as with endoscopic esophagitis and any pathologic finding on EGD. RESULTS
We identified 346 patients (82.7% female, median age 63 years, median disease duration 10 years, 23%
diffuse cutaneous SSc) satisfying the inclusion criteria, who completed UCLA GIT 2.0 questionnaires at
940 visits. EGD was recommended at 169 visits. In multivariable analysis, UCLA GIT 2.0 and some of
its subscales (reflux, distention/bloating, social functioning) were associated with the indication of EGD.
In 177 EGD performed in 145 patients, neither the total ULCA GIT 2.0 score nor any of its subscales
were associated with endoscopic esophagitis, nor with any pathologic EGD findings. CONCLUSIONS In
a real-life setting, the UCLA GIT 2.0 and its reflux subscale were able to discriminate patients with SSc
who had an indication for EGD, but did not correlate with findings in EGD. We conclude that, while
using the UCLA GIT 2.0 in the routine care of patients with SSc may help the rheumatologist to better
understand the burden of GI symptoms in the individual patient, it should not be used as a stand-alone
instrument to identify an indication of EGD.
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Abstract
Background and objectives: The University of California Los Angeles Scleroderma Clinical Trial Consortium
Gastrointestinal Tract Instrument 2.0 (UCLA GIT 2.0) is validated to capture gastrointestinal (GI) tract morbidity in
patients with systemic sclerosis (SSc). The aims of this study were to determine in a large SSc cohort if the UCLA
GIT 2.0 is able to discriminate patients for whom a rheumatologist with experience in SSc would recommend an
esophago-gastro-duodenoscopy (EGD), and if it could identify patients with endoscopically proven esophagitis or
with any pathologic finding on EGD.
Methods: We selected patients fulfilling the ACR/EULAR 2013 criteria for SSc from our EUSTAR center having
completed at least once the UCLA GIT 2.0 questionnaire, and we collected data on gastrointestinal symptoms and
EGD from their medical charts. We analyzed by general linear mixed effect models several parameters, including
UCLA GIT 2.0, considered as potentially associated with the indication of EGD, as well as with endoscopic
esophagitis and any pathologic finding on EGD.
Results: We identified 346 patients (82.7% female, median age 63 years, median disease duration 10 years, 23%
diffuse cutaneous SSc) satisfying the inclusion criteria, who completed UCLA GIT 2.0 questionnaires at 940 visits.
EGD was recommended at 169 visits. In multivariable analysis, UCLA GIT 2.0 and some of its subscales (reflux,
distention/bloating, social functioning) were associated with the indication of EGD. In 177 EGD performed in 145
patients, neither the total ULCA GIT 2.0 score nor any of its subscales were associated with endoscopic esophagitis,
nor with any pathologic EGD findings.
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Conclusions: In a real-life setting, the UCLA GIT 2.0 and its reflux subscale were able to discriminate patients with
SSc who had an indication for EGD, but did not correlate with findings in EGD. We conclude that, while using the
UCLA GIT 2.0 in the routine care of patients with SSc may help the rheumatologist to better understand the burden
of GI symptoms in the individual patient, it should not be used as a stand-alone instrument to identify an
indication of EGD.
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Introduction
In patients with systemic sclerosis (SSc), the gastro-
intestinal (GI) tract is the most common internal
organ involvement, with over two thirds of patients
reporting GI symptoms [1]. SSc GI tract involvement
is a major cause of serious morbidity, affecting
health-related quality of life (HRQoL) and survival of
these patients [2, 3]. The most prevalent GI manifest-
ation is esophageal involvement due to hypomotility
and gastroesophageal reflux, the latter often leading
to esophagitis and in later stages to Barrett’s esopha-
gus [4]. Another GI manifestation of SSc is gastric
antral vascular ectasia (GAVE) which may cause se-
vere anemia [5]. To date, there are no recommenda-
tions or guidelines when to perform endoscopic and
functional investigation of the upper GI tract in pa-
tients with SSc. Esophago-gastro-duodenoscopy (EGD)
plays a major role in the diagnosis of reflux esopha-
gitis, esophageal strictures, Barrett’s esophagus, and
adenocarcinoma of the esophagus.
The University of California at Los Angeles Sclero-
derma Clinical Trial Consortium GIT 2.0 instrument
(UCLA GIT 2.0) is a patient-completed questionnaire
validated to assess GI symptoms severity and related
HRQoL in SSc [6]. Originally developed in English,
and with a minimal clinically important difference
previously determined [6], it has been validated in dif-
ferent languages [7–11]. Several clinical trials of GI
treatments in patients with SSc already used this in-
strument as an outcome measurement [12–14]. The
UCLA GIT 2.0 is an excellent candidate to guide the
need for further investigation of the GI tract by en-
doscopy and/or functional tests. Constructed to reflect
the burden of GI symptoms including reflux, it is at-
tractive to hypothesize that it is able to identify pa-
tients with endoscopic esophagitis or other clinically
significant findings on EGD.
In this study, we aimed to determine, in an unselected,
real-life cohort of patients with SSc, whether the UCLA
GIT 2.0 could discriminate patients for whom a rheuma-
tologist with experience in SSc would recommend an
EGD, and if the UCLA GIT 2.0 could identify patients at




For this observational, post hoc analysis of prospectively
collected data from the SSc cohort of the University
Hospital Zurich, we selected patients who were included
in the European Scleroderma Trials and Research Group
(EUSTAR) database, fulfilled the ACR/EULAR 2013 cri-
teria for the classification of SSc, and completed at least
one UCLA GIT 2.0 questionnaire. Our center is follow-
ing the EUSTAR recommendations for a detailed annual
assessment, based on a standardized clinical approach
and work-up [1]. Patients also complete additional ques-
tionnaires at their annual visits as part of that routine
assessment, including the UCLA GIT 2.0. Investigations
of the GI tract, such as EGD, are not included in the
routine assessment and are selectively recommended by
the expert rheumatologist, after taking the history, per-
forming the clinical examination of the patients, and
evaluating their same-day work-up results (laboratory,
lung function tests, lung imaging, electrocardiogram,
and power-Doppler echocardiography). There was no
regular use of the UCLA GIT 2.0 questionnaire to de-
cide further GI investigation, although the rheumatolo-
gist could have access to the patient self-reported data,
at least in part of the cases.
Data were retrieved from the prospectively collected
EUSTAR registry for our center. In the EUSTAR data-
base, information on gastrointestinal involvement is re-
corded by 3 items: esophageal symptoms (reflux and/or
dysphagia), stomach symptoms (early satiety and/or
vomiting), and intestinal symptoms (diarrhea, bloating,
and/or constipation). To collect more detailed data on
upper GI symptoms, presence of EGD, and treatment
with proton pump inhibitors (PPI), we additionally
reviewed retrospectively the electronic medical records
(EMR) of the selected patients (see details in the online
supplement). We also recorded the attending rheumatol-
ogist’s indication to perform an EGD from each visit of
the patient. As some patients had more than one EGD,
we selected for further analysis the EGD performed
within a period of up to 3 months before or after the
corresponding EUSTAR assessment visit and, if more
than one EGD, the one closest to the corresponding
visit. Reflux esophagitis was graded according to the Los
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Angeles classification [15]. Patients with concomitant
acute GI bleeding or a history of cancer in the upper GI
tract were excluded from this study. The study has been
performed in accordance with the Declaration of
Helsinki Ethical Principles and with GCP guidelines.
Ethical approval for this data collection and analysis was
issued by the cantonal ethics (BASEC Nr. PB2016-01515
and 2018-02165).
UCLA GIT 2.0 questionnaire and study outcomes
The UCLA GIT 2.0 questionnaire contains 34 items, or-
ganized into seven subscales: reflux, distention/bloating,
diarrhea, fecal soilage, constipation, emotional wellbeing,
and social functioning. The subscales are scored from 0
to 3, higher scores indicating more severe symptomatol-
ogy and worse HRQoL. Scoring of the diarrhea and
constipation scales is different, ranging from 0 to 2 and
0 to 2.5, respectively. The total UCLA GIT 2.0 score is
calculated by averaging all subscales, except the one for
constipation, and ranges from 0 to 2.83 [6, 7].
We defined three study outcomes: first, the recom-
mendation to perform EGD by the SSc-specialized
rheumatologist; second, macroscopic esophagitis
identified on EGD (based on the EGD report and men-
tioning the Los Angeles grade of esophagitis), further re-
ferred to as “endoscopic esophagitis”; and third, any
significant pathologic finding on EGD, further referred
to as “pathologic EGD.” The latter included endoscopic
esophagitis, mycotic esophagitis, esophageal strictures,
Barrett’s esophagus, gastric antral vascular ectasia
(GAVE), peptic ulcers, and tumors.
Statistical analysis
For statistical calculations, we used the statistic software
IBM SPSS 25.0 and R language 3.6 (lme4 package) [16].
A p value < 0.05 was considered statistically significant.
Numeric variables are described as median and inter-
quartile range (Q1, Q3), while categorical variables are
described as n and percentage. Comparisons between
groups were performed with the chi-squared test for cat-
egorical variables and with the Mann-Whitney U test for
numeric variables.
The parameters of interest for all three study out-
comes were the UCLA GIT 2.0 total score and its reflux,
distention/bloating, social functioning, and emotional
wellbeing subscales. We analyzed their association with
each of the three dichotomous outcomes of the study
using multivariable generalized linear mixed effects
models (GLMM) adjusted for random effects of subjects
and fixed effects for all other candidate parameters men-
tioned. For the first outcome (recommendation to per-
form EGD), we excluded patients who had performed
EGD during the last 3 months before their visit to our
center, considering that in most of these patients a new
EGD would not be recommended again at the
assessment.
The following parameters, which potentially influence
the study outcomes (further referred as “covariates”)
were selected by the authors based on clinical experience
and evidence from published literature: age, sex, disease
duration, cutaneous subset of SSc (diffuse vs. any other
subset) [17], modified Rodnan skin score (mRSS), body
mass index (BMI), hemoglobin (Hb), erythrocyte sedi-
mentation rate (ESR), forced vital capacity (FVC), PPI
therapy, gastro-esophageal symptoms as retrieved from
the charts of the patients (heartburn, regurgitation, dys-
phagia, and vomiting), “esophageal symptoms” as re-
corded in the EUSTAR database (reflux and/or
dysphagia), and “stomach symptoms” as recorded in the
EUSTAR database (early satiety and/or vomiting).
For the outcome “recommendation to perform EGD,”
we performed the following GLMM models using as co-
variates: 1. age, sex, disease duration, mRSS, SSc subset,
BMI, Hb, ESR, FVC, and PPI therapy, which were in-
cluded in all the other models; 2. gastro-esophageal
symptoms, as collected from the patient charts (heart-
burn, regurgitation, dysphagia, vomiting); 3. “esophageal
symptoms” and “stomach symptoms” as recorded in
EUSTAR database; and in models 4 to 8, one of the se-
lected subscales of UCLA GIT 2.0 (reflux, distention/
bloating, social functioning, emotional wellbeing) or the
UCLA GIT 2.0 total score, respectively.
For the outcomes “endoscopic esophagitis” and
“pathologic EGD,” anticipating that the number of EGD
will be less than one third than the number of visits with
a completed UCLA GIT 2.0 questionnaire, we reduced,
by clinical judgment, the number of covariates included
in the multivariable analysis. Consequently, all GLMM
models for these outcomes included only four independ-
ent variables, selected by clinical judgment: age, sex, dis-
ease duration, and PPI therapy. Further GLMM models
included these four parameters and one of the following
parameters, or group of parameters: mRSS (model 2),
Hb (model 3), gastroesophageal symptoms reported by
the patient: heartburn, regurgitation, and dysphagia, as
collected from EMR (model 4), “esophageal symptoms”
and “stomach symptoms” (model 5), and one of the se-
lected subscales of UCLA GIT 2.0 or the UCLA GIT 2.0
total score, respectively (models 6 to 10).
We further identified by receiver operating character-
istic (ROC) curve analysis, selecting the values with the
largest area under the curve (AUC) and significant 95%
confidence intervals (95% CI), cutoffs for the reflux, and
total UCLA GIT 2.0 score discriminating best between
patients with recommendation to perform EGD and
those without. Based on the AUC, the accuracy of the
prediction model can be considered excellent (0.9–1.0),
good (0.8–0.9), fair (0.7–0.8), or poor (0.6–0.7).
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Results
Patients and baseline characteristics
Out of 494 patients in the database, 346 were fulfilling
the inclusion criteria. For these, 940 visits with a com-
pleted UCLA GIT 2.0 questionnaire were available. The
median number of visits per patient was 2 (Q1, Q3: 1–
4), with 89/346 patients having one visit. Median follow-
up time was 3.4 years (Q1, Q3: 1.8–4.9).
The demographic and clinical data of the patients are
displayed in Table 1. The majority of participants were
female (82.4%) and Caucasian (94.5%), 23% had the dif-
fuse cutaneous subtype of SSc, with a median age of 63
years and a median disease duration of 10 years. Nine
out of 343 patients had a history of Barrett’s esophagus.
Of 346 patients, 261 patients (75.4%) reported GI symp-
toms and 311/346 patients (89.9%) had UCLA GIT 2.0
scores > 0 in at least one visit, GI symptoms recorded
from the patients’ charts and UCLA GIT 2.0 scores
(median and interquartile range) are displayed in Table 2.
The reflux and distention/bloating subscales and the
total score of UCLA GIT 2.0 had medians of 0.25, 0.50,
and 0.22, respectively, while the medians of the other
subscales were zero. Approximately 10% of the compo-
nents of the UCLA GIT 2.0 questionnaire were missing
overall. Of 940 visits, treatment with PPI was present in
588 (62.6%) visits at the time of completing the UCLA
GIT 2.0 questionnaire at the annual assessment.
Evaluation of the UCLA GIT 2.0 as a potential decision-
aiding instrument for EGD
Of 940 visits with completed UCLA GIT 2.0 question-
naires, 31 were excluded from this part of the analysis
because patients had an EGD within 3 months before
the visit. In the 909 remaining visits, EGD was recom-
mended in 169, of which 120 were carried out (Figure
S1 in the online supplement). Patients with a
Table 1 Baseline demographic and clinical characteristics of the study cohort
N
Age (years): median (Q1–Q3) 346 63 (51–72)
Disease duration (years): median (Q1–Q3) 346 10 (7–17)
BMI (kg/m2): median (Q1–Q3) 310 23.4 (21–27)
Male sex: N (%) 346 60 (17.3)
Diffuse cutaneous subset: n (%) 283 65 (23)
Raynaud’s phenomenon: n (%) 342 327 (95.6)
Digital ulcers ever: n (%) 335 114 (34.0)
mRSS: median (Q1–Q3) 337 3 (0–8)
Joint synovitis: n (%) 344 61 (17.7)
Joint contractures: n (%) 340 99 (29.1)
Esophageal symptoms (reflux, dysphagia): n (%) 344 185 (53.8)
Stomach symptoms (early satiety, vomiting): n (%) 341 102 (29.9)
Intestinal symptoms (diarrhea, bloating, constipation): n (%) 344 124 (36)
Malabsorption syndrome: n (%) 306 7 (2.3)
Intestinal pseudo-obstruction: n (%) 311 4 (1.3)
Barrett’s esophagus 343 9 (2.6)
Pulmonary hypertension: n (%) 331 35 (10.6)
Thorax HRCT: lung fibrosis: n (%) 328 135 (41.2)
FVC: median (Q1–Q3) 339 97 (84–110)
Renal crisis: n (%) 343 6 (1.7)
ANA positive: n (%) 345 340 (98.6)
Anti-centromere positive: n (%) 327 155 (47.4)
Anti-topoisomerase I positive: n (%) 332 84 (25.3)
Anti-RNA polymerase III positive: n (%) 310 36 (11.6)
CRP (mg/dl): median (Q1–Q3) 312 1.6 (0.7–4)
ESR (mm/h): median (Q1–Q3) 329 12 (6–23.5)
Hb (g/dl): median (Q1–Q3) 310 13.2 (12.4–14.1)
BMI body mass index, mRSS modified Rodnan skin score, HRCT high-resolution computer tomography, FVC forced vital capacity, ANA anti-nuclear antibodies, CRP
C-reactive protein, ESR erythrocyte sedimentation rate, Hb hemoglobin
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recommendation for EGD had significantly more fre-
quent heartburn, dysphagia, and regurgitation, a history
of Barrett’s esophagus, as well as higher mRSS scores
and erythrocyte sedimentation rates; they also had sig-
nificantly higher values of the UCLA GIT 2.0 score and
all its subscales except the subscale for fecal soilage
(Table 3).
We next aimed to identify independent parameters as-
sociated with the expert recommendation to perform
EGD. We found in multivariable GLMM models that
mRSS, individual gastroesophageal symptoms (heart-
burn, dysphagia, and regurgitation, respectively) and
upper gastrointestinal tract symptoms as recorded in the
EUSTAR database (“esophageal symptoms” and “stom-
ach symptoms”), significantly associated with the recom-
mendation to perform EGD. Except the emotional
wellbeing subscale, all the examined subscales of UCLA
GIT 2.0, as well as the total score, correlated signifi-
cantly with the recommendation to perform EGD
(Table 4).
To identify optimal cutoffs for the reflux and total
UCLA GIT 2.0 score, discriminating best between pa-
tients with recommendation to perform EGD and those
without, we performed ROC analysis. For the reflux sub-
scale, the best results were found for the cutoff of 0.163
(AUC [95% CI] of 0.64 [0.60–0.68]), with a sensitivity of
73% and specificity of 50%. Similarly, for the total UCLA
GIT 2.0 score, we identified the optimal cutoff of 0.161,
with an AUC [95%CI] of 0.64 [0.59–0.68], sensitivity
78%, and specificity 46%. As the range for these scores is
0–3 and 0–2.83 respectively, this shows that even pa-
tients with a low symptom burden have been referred to
further evaluation by EGD.
Evaluation of the UCLA GIT 2.0 as a potential predictor of
endoscopic esophagitis and pathologic EGD
Of all 346 patients, 241 had undergone EGD at least
once during the entire observation period. We identified
177 EGD matching the inclusion criteria, performed in
145 patients.
Of these, 128 were performed on indication from the
SSc-expert rheumatologist of our center, and 49 were
performed on indication from another physician, of
which 31 were done during the 3 months preceding the
visit (Figure S2 in the online supplement). A single EGD
was performed in 118 patients, 22 patients had under-
gone two EGDs, and five patients had undergone three
EGDs. The median time between the visit and the corre-
sponding EGD was 2 days (Q1, Q3: − 0.5, 36), with a
mean of 9.7 days.
Esophagitis was found in 52/177 EGD (in 50 patients),
GAVE in 15/177 EGD (in 12 patients), and biopsy-
verified Barrett’s esophagus in 24 /177 EGD (in 19 pa-
tients). Other EGD findings were fungal esophagitis in 7,
esophageal strictures in 2, peptic ulcers of the stomach
or bulbus duodeni in 3, and gastritis in 6 EGD, leading
to a total of 94/177 pathologic EGD.
Patients with endoscopic esophagitis had significantly
more frequently EUSTAR reported esophageal symp-
toms (“reflux and/or dysphagia”) and slightly higher
mRSS scores, while the distribution of individual upper
gastrointestinal tract symptoms (heartburn, dysphagia,
and regurgitation), as well as that of the UCLA GIT 2.0
score and subscales, did not reach statistical significance
(Table 5). Patients with esophagitis also tended to be less
frequently under treatment with PPI (52.7% vs. 72.4%,
p = 0.057) while, surprisingly, they had slightly but sig-
nificantly higher Hb values vs. patients without esopha-
gitis (median Hb value13.6 g/dl vs 12.9 g/dl, p = 0.008).
We next wanted to analyze whether clinical parame-
ters can be identified that are independently associated
with the presence of esophagitis or other pathologic GI
tract findings. In multivariable GLMM analysis on the
outcome of endoscopic esophagitis, mRSS and EUSTAR
reported esophageal symptoms (“reflux and/or dyspha-
gia”) were the only parameters associated with endo-
scopic esophagitis; however, the associations were very
weak (with an OR of only 1.1 for mRSS and a low AUC
of 0.61 for esophageal symptoms) (Table 6). Hemoglobin
correlated with endoscopic esophagitis in the univariable
model, but not in the multivariable model. The UCLA
Table 2 Gastrointestinal symptoms and scores of the UCLA GIT





Early satiety 106 (11.6)
Vomiting 34 (3.7)




Fecal incontinence 58 (6.3)
UCLA GIT 2.0 subscales Median Q1, Q3 Range
Reflux 0.25 0.00, 0.63 (0–3)
Distention/bloating 0.50 0.00, 1.00 (0–3)
Fecal soilage 0.00 0.00, 0.00 (0–3)
Diarrhea 0.00 0.00, 0.50 (0–2)
Social functioning 0.00 0.00, 0.33 (0–2.5)
Emotional wellbeing 0.00 0.00, 0.22 (0–3)
Constipation 0.00 0.00, 0.50 (0–2.5)
Total score of UCLA GIT 2.0 0.22 0.07, 0.49 (0–2.4)
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GIT 2.0 total score and its subscales showed no associ-
ation with endoscopic esophagitis. Similar negative re-
sults were obtained in the GLMM analysis for the
outcome of pathologic EGD (Table S1 in the online sup-
plement), suggesting that in our real-life cohort, the
UCLA GIT 2.0 failed to identify patients with EGD
findings.
Discussion
To our best knowledge, this is the first study to analyze
the performance of the UCLA GIT 2.0 in a large real-life
cohort of unselected patients with SSc. Our results show
that the UCLA GIT 2.0 score and its reflux subscale
identified patients with SSc, in whom EGD was recom-
mended by experts, with a sensitivity of over 70% and a
specificity of about 50%.
The recommendation for EGD was made in all pa-
tients by a rheumatologist with experience in SSc, at the
annual visit of the patient and following a comprehen-
sive investigation, as defined by the EUSTAR guidelines
[1]. There was no regular use of the UCLA GIT 2.0
questionnaire to decide further GI tract investigation.
We excluded patients with concomitant acute GI bleed-
ing or a history of cancer in the upper GI tract, as in
Table 3 Comparison of patient data from visits in which EGD was recommended (n = 169) vs. data from visits in which EGD was
not recommended (n = 740)
Referral to EGD
Median (Q1, Q3)
No referral to EGD
Median (Q1, Q3)
p*
Age 63 (52, 70.5) 63 (53, 72) 0.759
Disease duration 11 (7, 20) 10 (6,16) 0.086
mRSS 3 (0, 8) 2 (0, 6) 0.009
FVC 98 (85, 109) 97 (85, 110) 0.813
BMI 23.7 (21.4–26.7) 23.4 (21, 27) 0.712
Hemoglobin 13.1 (12, 14.2) 13.3 (12.4, 14.1) 0.118
ESR 16 (9, 26) 12 (6, 22) 0.013
n (%) n (%) p#





Heartburn 105 (60.7) 207 (29) < 0.001
Regurgitation 41 (23.7) 78 (10.9) < 0.001
Dysphagia 65 (38.5) 112 (15.6) < 0.001
Vomiting 10 (5.9) 22 (3.1) 0.074
Esophageal symptoms 109 (72.2) 283 (43.5) < 0.001
Stomach symptoms 66 (44.3) 139 (21.4) < 0.001
Barrett’s esophagus 17 (10.1) 5 (0.7) < 0.001
PPI therapy 76 (62.3) 18 (81.8) 0.077
Digital ulcers 16 (16) 65 (15) 0.811
Joint contractures 46 (31.1) 226 (35.1) 0.354
UCLA GIT 2.0 subscales Median (Q1, Q3) Median (Q1, Q3) p*
Reflux 0.50 (0.13, 0.88) 0.14 (0.00, 0.50) < 0.001
Distention/bloating 0.75 (0.25, 1.46) 0.25 (0.00, 1.00) < 0.001
Fecal soilage 0.00 (0.00, 1.00) 0.00 (0.00, 0.00) 0.067
Diarrhea 0.00 (0.00, 0.50) 0.00 (0.00, 0.50) 0.028
Social functioning 0.33 (0.00, 0.60) 0.00 (0.00, 0.33) < 0.001
Emotional wellbeing 0.11 (0.00, 0.75) 0.00 (0.00, 0.22) < 0.001
Constipation 0.25 (0.00, 0.75) 0.00 (0.00, 0.50) 0.004
Total score of UCLA GIT 2.0 0.35 (0.17, 0.70) 0.19 (0.05, 0.44) < 0.001
Statistically significant results are highlighted in bold font
*Mann-Whitney U test, #Chi-square test
mRSS modified Rodnan skin score, FVC forced vital capacity, BMI body mass index, Hb hemoglobin, ESR erythrocyte sedimentation rate, PPI proton pump inhibitors
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these cases, the indication for EGD would be driven by
other criteria than the symptoms captured by the UCLA
GIT 2.0.
Considering that several clinical or laboratory data
might influence the indication of EGD, or might predict
EGD findings, we adjusted the analyses for all these pa-
rameters, which were included as covariates for the
GLMM models after a careful selection based on clinical
judgment and evidence from published literature. For
example, we expected the recommendation for EGD to
be favored by anemia, possibly caused by gastrointestinal
bleeding, which is frequent in SSc, especially in the pres-
ence of GAVE [5]; however, our data did not show any
association between Hb and the referral to EGD. On the
other hand, mRSS was significantly associated with the
recommendation for EGD, but the very small OR sug-
gests that this association is of little clinical significance.
As expected, patients with a history of Barrett’s esopha-
gus were more frequently referred to EGD. We did not
have enough data on significant weight loss or decrease
in Hb, and no data on other objective markers of GI in-
volvement, such as F-calprotectin, to include these
among the selected covariates.
The recommendation to perform EGD was signifi-
cantly associated with higher UCLA GIT 2.0 reflux, dis-
tention/bloating, and social functioning subscale scores,
as well as with higher total scores. As expected, we
found similar significant associations for individual
symptoms like heartburn, dysphagia, and regurgitation,
as well as for these symptoms clustered together as
esophageal symptoms and stomach symptoms. These re-
sults support the use of the UCLA GIT 2.0 questionnaire
in practice, as it provides the attending rheumatologist
with detailed information on gastrointestinal symptoms
and helps orientating the further investigation of the GI
tract.
In the second part of the study, we analyzed the hy-
pothesis that the reflux subscale or the total score of the
Table 4 Factors associated with referral to EGD (multivariable generalized linear mixed effects models, GLMM). Statistically significant
results are highlighted in bold font
Multivariable GLMM
Parameters Models* OR 95% CI p AUC (95% CI)
Age Model 1 0.99 0.97–1.01 0.269 0.75 (0.69–0.80)
Sex 0.66 0.33–1.33 0.242
Disease duration 1.00 0.98–1.02 0.926
SSc subset 1.27 0.67–2.40 0.471
mRSS 1.05 1.00–1.10 0.030
Hb 0.89 0.74–1.07 0.218
PPI 0.80 0.49–1.30 0.363
BMI 1.03 0.97–1.09 0.294
FVC 1.00 0.99–1.01 0.948
ESR 1.00 0.99–1.02 0.943
Barrett’s esophagus 24.4 2.43–245.18 0.007
Heartburn Model 2 2.23 1.35–3.69 0.002 0.71 (0.65–0.76)
Regurgitation 2.09 1.14–3.81 0.017
Dysphagia 3.01 1.79–5.05 < 0.001
Vomiting 1.98 0.62–6.25 0.247
Esophageal symptoms Model 3 1.91 1.14–3.18 0.013 0.68 (0.62–0.74)
Stomach symptoms 2.12 1.24–3.61 0.006
Reflux subscale Model 4 1.86 1.19–2.90 0.006 0.68 (0.62–0.74)
Distention/bloating subscale Model 5 1.50 1.12–2.01 0.007 0.70 (0.65–0.76)
Social functioning Model 6 2.57 1.56–4.23 < 0.001 0.65 (0.59–0.71)
Emotional wellbeing Model 7 1.32 0.80–2.19 0.274 0.68 (0.62–0.74)
Total UCLA GIT 2.0 score Model 8 2.16 1.21–3.83 0.009 0.64 (0.58–0.70)
*Model 1 contains the covariates age, sex, disease duration, PPI therapy, mRSS, ESR, Hb, FVC, Barrett’s esophagus, BMI, and a subset of SSc. All other models
contain, in addition to the covariates of model 1, the following covariates: model 2: heartburn, regurgitation, dysphagia, and vomiting; model 3: the symptom
clusters “esophageal symptoms” and “stomach symptoms” as per expert opinion; and models 4–8: one of the mentioned subscales of UCLA GIT 2.0, respectively
the total UCLA GIT 2.0 score
mRSS modified Rodnan skin score, Hb hemoglobin, ESR erythrocyte sedimentation rate, PPI proton pump inhibitors, FVC forced vital capacity, BMI body mass index
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UCLA GIT 2.0 would be associated with endoscopic
esophagitis or with a pathologic EGD in general. Data
on the associations of the UCLA GIT 2.0 with objective
upper GI tract findings in patients with SSc are scarce.
Previous studies analyzed smaller groups of selected pa-
tients, in whom GI tract investigation and completion of
the UCLA GIT 2.0 were performed systematically and
within a narrow time interval [18–20]. A prospective
study on 55 patients with SSc and clinically significant
upper GI tract symptoms found a moderate correlation
between the reflux scale of the UCLA GIT 2.0 with
endoscopic esophagitis; the reflux subscale was also dis-
criminative between patients with and without
pathologic findings on esophageal manometry [18]. An-
other study on 40 patients with SSc, of whom 85% re-
ported upper GI tract symptoms, found an association
of higher reflux and total UCLA GIT 2.0 scores with de-
creased amplitude of distal esophageal contractions [19].
A very recent study on 31 patients with SSc, assessing
esophageal motility dysfunction by scintigraphy, found a
significant association of esophageal emptying activity
with the GIT 2.0 reflux score, but not with the other
subscales and the total UCLA GIT 2.0 score [20].
In our study on a large cohort of real-life patients, nei-
ther the total UCLA GIT 2.0 score nor the reflux sub-
scale correlated with endoscopic esophagitis. The only
Table 5 Comparison of patient data from visits in which EGD detected esophagitis (n = 52), respectively did not detect






Age 62 (51, 69.5) 64 (56, 72) 0.086
Disease duration 10 (6, 19) 12 (7, 19) 0.487
mRSS 5 (0, 11.75) 2 (0, 6) 0.002
FVC 93.5 (76.5, 110.8) 99 (84, 108) 0.528
BMI 23.2 (21.6, 25.9) 23.8 (21.1, 28.1) 0.407
Hb 13.6 (12.4, 14.6) 12.9 (11.6, 13.7) 0.006
ESR 18 (8, 28) 16 (10, 28) 0.888
n (%) n (%) p#





Barrett’s esophagus 9 (17.3) 15 (12) 0.347
Heartburn 32 (64) 62 (50.4) 0.104
Regurgitation 13 (26) 25 (20.3) 0.414
Dysphagia 18 (36) 46 (37.4) 0.863
Vomiting 5 (10) 5 (4.1) 0.129
Esophageal symptoms 40 (81.6) 67 (60.4) 0.008
Stomach symptoms 22 (46.8) 39 (35.5) 0.163
PPI therapy 30 (57.7) 89 (72.4) 0.057
Digital ulcers 9 (27.3) 11 (15.7) 0.217
Joint contractures 16 (33.3) 32 (29.1) 0.594
UCLA GIT 2.0 subscales Median (Q1, Q3) Median (Q1, Q3) p*
Reflux 0.50 (0.25, 0.84) 0.38 (0.13, 0.88) 0.534
Distention/bloating 0.50 (0.06, 1.00) 0.75 (0.25, 1.50) 0.069
Fecal soilage 0.00 (0.00, 0.00) 0.00 (0.00, 1.00) 0.535
Diarrhea 0.00 (0.00, 0.50) 0.00 (0.00, 0.50) 0.708
Social functioning 0.17 (0.00, 0.50) 0.17 (0.00, 0.50) 0.283
Emotional wellbeing 0.00 (0.00, 0.33) 0.11 (0.00, 0.44) 0.337
Constipation 0.00 (0.00, 0.50) 0.25 (0.00, 0.75) 0.404
Total score of UCLA GIT 2.0 0.27 (0.16, 0.61) 0.37 (0.13, 0.74) 0.452
Statistically significant results are highlighted in bold font. *Mann-Whitney U test, #Chi-square test
mRSS modified Rodnan skin score, FVC forced vital capacity, BMI body mass index;, Hb hemoglobin, ESR erythrocyte sedimentation rate, PPI proton
pump inhibitors
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parameters showing associations with this outcome were
the EUSTAR-recorded “esophageal symptoms” (defined
as the presence of reflux and/or dysphagia), and the
mRSS. For the latter, the very low OR suggests the asso-
ciation is of little clinical importance. Not surprisingly,
the symptom interpretation by the physician (as pres-
ence or absence of “esophageal symptoms”) performed
better than single symptoms such as “heartburn”, as re-
corded in the patient EMR, in detecting patients with
esophagitis.
The lack of correlation between esophagitis and single
symptoms or the UCLA GIT 2.0 reflux scale may be ex-
plained by several factors, among which the non-
systematic use of EGD, the variable time between EGD
and the UCLA GIT 2.0 completion, and the use of PPI
in about 60% of patients. Moreover, large studies per-
formed by gastroenterologists in patients with gastro-
esophageal reflux disease (GERD) have shown that an
expert history, as well as GERD questionnaires, such as
the reflux disease questionnaire and gastroesophageal re-
flux disease questionnaire, have important limitations
when compared with objective testing for GERD by
EGD or functional testing [21–23]. Studies with system-
atic EGD in unselected patients with SSc are scarce [24,
25]. In a single-center SSc cohort study, Petcu et al.
found endoscopic esophagitis in 8/22 patients without
any GI symptoms and in 39/57 patients with GI
symptoms. Only 12/26 patients with gastroesophageal
reflux symptoms had esophagitis on endoscopy [24].
The authors advocate for the routine use of EGD during
the early stage of SSc, even in the absence of typical
symptoms.
The strengths of our study rely in the large, real-life
cohort of unselected patients from a tertiary SSc center
with long-standing experience, and in the statistical
methods applied, which allow adjusting for a large num-
ber of independent parameters potentially associated
with the study outcomes. The study also has several lim-
itations, which include the partially retrospective data
collection. However, the large majority of the data were
collected prospectively following the EUSTAR recom-
mendations [1]. There was considerable variability in
performing EGD, as in some patients this was not done
despite being recommended, and in others it may have
been done in another center, with the results not re-
corded in the EMR of our hospital. However, over 70%
of EGD recommended by our center were performed
and the respective results were available in the hospital
EMR. It is possible that some reports of EGD performed
outside our hospital may have not reached us, but we as-
sume that in many of these cases EGD was probably not
done, as our center strives to obtain all medical informa-
tion of the patients and communication between local
medical facilities is generally good. Another limitation is
Table 6 Factors associated with esophagitis on EGD (multivariable linear mixed effects models, GLMM)
Multivariable GLMM
Parameters Models* OR 95% CI p AUC (95%CI)
Age Model 1 0.98 0.96–1.01 0.289 0.69 (0.60–0.79)
Sex 0.89 0.34–2.31 0.803
Disease duration 1.00 0.96–1.03 0.925
PPI 0.50 0.21–1.23 0.133
mRSS Model 2 1.11 1.04–1.18 0.003 0.76 (0.67–0.84)
Hb Model 3 1.33 1.00–1.77 0.051 0.89 (0.83–0.95
Heartburn Model 4 1.71 0.76–3.83 0.193 0.64 (0.55–0.73)
Regurgitation 1.43 0.59–3.46 0.433
Dysphagia 1.01 0.46–2.18 0.987
Esophageal symptoms Model 5 3.25 1.00–10.54 0.049 0.61 (0.52–0.71)
Stomach symptoms 1.43 0.57–3.60 0.443
Reflux subscale Model 6 1.17 0.60–2.26 0.644 0.60 (0.51–0.69)
Distention/bloating subscale Model 7 0.69 0.43–1.12 0.135 0.66 (0.58–0.75)
Social functioning Model 8 0.70 0.33–1.50 0.362 0.59 (0.50–0.68)
Emotional wellbeing Model 9 0.91 0.43–1.95 0.810 0.64 (0.55–0.73)
Total UCLA GIT 2.0 score Model 10 0.82 0.33–2.02 0.659 0.68 (0.59–0.77)
General linear mixed models. Statistically significant results are highlighted in bold font
*Model 1 contains the covariates age, sex, disease duration and PPI therapy. All other models contain, in addition to the covariates of model 1, the following
covariates: model 2: mRSS; model 3: hemoglobin; model 4: the symptoms heartburn, regurgitation, dysphagia, and vomiting; model 5: the symptom clusters
“esophageal symptoms” and “stomach symptoms” as per expert opinion; models 6–10: one of the mentioned subscales of UCLA GIT 2.0, respectively the total
UCLA GIT 2.0 score
PPI proton pump inhibitors, Hb hemoglobin, mRSS modified Rodnan skin score
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the time of ± 3 months allowed between questionnaire
completion and EGD, which is quite long and may have
contributed to the lack of correlation between UCLA
GIT 2.0 scores and the results of the EGD. Finally, yet
importantly, treatment with PPI was not recorded into
detail and we were not able to analyze the indication for
PPI, doses, or compliance.
Conclusions
In a large real-life cohort of unselected patients with
SSc, we found a significant association of the UCLA GIT
2.0 score with the interpretation of GI symptoms by
rheumatologists and consecutive recommendations for
EGD. However, there was no association between the
UCLA GIT 2.0 score, or its subscales, with endoscopic
esophagitis, nor with any pathologic findings on EGD.
Even the correlation between single symptoms, such as
heartburn and dysphagia, and endoscopic esophagitis,
was poor. We conclude that, while using the UCLA GIT
2.0 in the routine care of patients with SSc may help the
rheumatologist to better understand the burden of GI
symptoms in the individual patient, it should not be
used as a stand-alone instrument to identify an indica-
tion of EGD. The question of whether all or selected pa-
tients with SSc should be investigated by EGD needs to
be addressed by further studies.
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